I am a n00b within the biotech sector!
I couldn't figure out whether the news was good, bad or neutral in terms of screening failure rates.
It appears that it is (perhaps) neutral, and the there may be slightly increased trial costs?
Interesting articles for other n00bs out there that had no idea what the announcement meant..
http://firstclinical.com/journal/2008/0807_Screen_Failures.pdf
Cheers,
JJR
ha-irinotecan phase iii clinical trial update , page-3
Add TSN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| TSN (ASX) Chart |
Day chart unavailable